ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer.

Jane Hook; Sally Patricia Stenning; James Brenton; Stan B Kaye; Iain A. McNeish; Raj Naik; Timothy Perren; Jennifer Petrie; Laura Farrelly; Andrew Peter Dean; Dearbhaile M. O'Donnell; Dolores Gallardo Rincon; Jae Weon Kim; Jonathan A. Ledermann; Andrew R. Clamp;

doi:10.1200/jco.2014.32.15_suppl.tps5611

ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5611 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5611-TPS5611 ◽

Cited By ~ 2

Author(s):

Jane Hook ◽

Sally Patricia Stenning ◽

James Brenton ◽

Stan B Kaye ◽

Iain A. McNeish ◽

...

Keyword(s):

Randomized Trial ◽

Fallopian Tube ◽

Weekly Paclitaxel ◽

Newly Diagnosed ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Weekly Treatment ◽

Dose Dense

Download Full-text

Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.5506 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5506-5506 ◽

Cited By ~ 18

Author(s):

S. Isonishi ◽

M. Yasuda ◽

F. Takahashi ◽

N. Katsumata ◽

E. Kimura ◽

...

Keyword(s):

Fallopian Tube ◽

Gynecologic Oncology ◽

Phase Iii ◽

Weekly Paclitaxel ◽

Phase Iii Trial ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Dose Dense

Download Full-text

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyq182 ◽

2010 ◽

Vol 41 (2) ◽

pp. 278-282 ◽

Cited By ~ 21

Author(s):

K. Fujiwara ◽

E. Aotani ◽

T. Hamano ◽

S. Nagao ◽

H. Yoshikawa ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Weekly Dose ◽

Newly Diagnosed ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Randomized Phase Ii ◽

Dose Dense

Download Full-text

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70363-2 ◽

2013 ◽

Vol 14 (10) ◽

pp. 1020-1026 ◽

Cited By ~ 264

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Seiji Isonishi ◽

Fumiaki Takahashi ◽

Hirofumi Michimae ◽

...

Keyword(s):

Fallopian Tube ◽

Long Term Results ◽

Open Label ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Open Label Trial ◽

Dose Dense ◽

Randomised Controlled

Download Full-text

Saracatinib (AZD0530) plus weekly paclitaxel in platinum resistant ovarian, fallopian tube or primary peritoneal cancer

http://isrctn.org/> ◽

10.1186/isrctn32163062 ◽

2012 ◽

Author(s):

Lee Webber

Keyword(s):

Fallopian Tube ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

Dose-fractionated chemotherapy compared to standard chemotherapy, following surgery in women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer

http://isrctn.org/> ◽

10.1186/isrctn10356387 ◽

2012 ◽

Author(s):

Janet Cairns

Keyword(s):

Fallopian Tube ◽

Newly Diagnosed ◽

Standard Chemotherapy ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.06.032 ◽

2021 ◽

Author(s):

Floor J. Backes ◽

Lai Wei ◽

Min Chen ◽

Kasey Hill ◽

Kyle Dzwigalski ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.04.533 ◽

2016 ◽

Vol 141 ◽

pp. 207 ◽

Cited By ~ 2

Author(s):

U.A. Matulonis ◽

M. Sill ◽

P.H. Thaker ◽

J.W. Carlson ◽

C.J. Darus ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Randomized Phase Ii

Download Full-text

Abstract CT151: A Phase II study of NLG207 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

10.1158/1538-7445.am2019-ct151 ◽

2019 ◽

Cited By ~ 1

Author(s):

Linda Duska ◽

David M. O'Malley ◽

Carolyn Krasner ◽

Russell J. Schilder ◽

Cara Mathews ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5578 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5578-5578

Author(s):

Isabelle Ray-Coquard ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text